Xenon Pharmaceuticals Inc. has amended its 2025 Inducement Equity Incentive Plan to increase the number of shares allocated from 775,000 to 900,000 for stock options and performance awards, effective November 24, 2025. This change did not require shareholder approval, per Nasdaq rules.